Hematology-OncologyBệnh bạch cầu lympho mạn tính dòng B (Chronic Lymphocytic Leukemiadel(17p)
Targeting ROR1 in Chronic Lymphocytic Leukemia: Insights from the Zilovertamab and Ibrutinib Combination in High-Risk del(17p) Disease
By MedXY|Oct 6, 2026
A phase 1b/2 study evaluating zilovertamab combined with ibrutinib in relapsed/refractory CLL reveals safety, mechanistic inhibition of ROR1 signaling pathways, and a potential efficacy signal in del(17p) patients warranting further studies